This article is more than 5 years old. Information may no longer be current.
New NSAID effective in studies of post-cataract surgery inflammation
IRVINE, Calif. — A topical, twice-daily nonsteroidal anti-inflammatory drug being developed for the treatment of ocular inflammation showed success in two phase 3 studies, according to a press release on the studies.
Robert H. Stewart, MD, and colleagues with Houston Eye Associates evaluated the drug, Xibrom (bromfenac, Ista/Senju), in a randomized trial. They assigned 527 patients who had undergone cataract surgery to receive either Xibrom or placebo twice a day for 14 days.
Success was defined as the complete absence of ocular inflammation.
On day 15, 64% of Xibrom-treated patients achieved success, compared with 43% of patients receiving placebo. The compound was well tolerated with a lower incidence of ocular adverse events compared with the placebo treatment group as well, the press release said.
Ista Pharmaceuticals, the drug’s U.S. marketer, expects to launch Xibrom in the United States during the first half of 2005. Developer Senju Pharmaceuticals has been marketing the drug in Japan since 2000.